All articles by Raghavi Joshi

Raghavi Joshi

M&As this week: JW Pharmaceutical, Lonza, Karo Intressenter

JW Pharmaceutical has acquired a 25% stake in Argonaut Therapeutics through a $2.6m investment.

M&As this week: Datinvest, Shanghai Pharmaceuticals, Sunrise Bright Investment

Canadian company Datinvest International (Datinvest) has signed an agreement to purchase all the outstanding shares and share capital issued by biopharmaceutical company Exxel Pharma.

Deals this week: Cipla, Takeda Pharmaceutical, Cadila Healthcare

Indian pharmaceutical company Cipla plans to issue non-convertible debentures or bonds through a public offering or a private placement to raise Rs20bn ($293.2m).

M&As this week: Eli Lilly, Fujifilm Holdings, Canopy Growth

US-based healthcare company Eli Lilly and Company has agreed to acquire AurKa Pharma Inc. 

Deals this week: GlaxoSmithKline, Ligand, Catalent Pharma Solutions

GlaxoSmithKline Plc (GSK) has issued 1.25% international bonds due May 2026 in a public offering to raise ‎€1bn ($1.19bn). 

M&As this week: Strides Shasun, Takeda Pharmaceutical, Eli Lilly

Indian bio-pharmaceuticals developer Strides Shasun has signed an agreement with Apotex to merge with the latter’s Australian subsidiary, Apotex.

Deals this week: MannKind, XtalPi, Ascendia Pharmaceuticals

Indian biopharmaceutical company MannKind has agreed to sign a marketing and distribution agreement with Cipla for the inhaled insulin drug, Afrezza.

Deals this week: IntelGenx, Oasmia Pharmaceutical, Karo Pharma

Canadian oral drug delivery company IntelGenx Technologies plans to issue 300 units priced at $10,000 a unit in a private placement to raise $3m in Canada and the US.

M&As this week: United Therapeutics, Par Formulations, Endo Ventures

United Therapeutics Corporation has agreed to acquire SteadyMed for $216m.

Deals this week: CTD Holdings, Peptron, Hemispherx Biopharma

US-based biotechnology company CTD Holdings has completed issuing 20,000 units of series B convertible preferred stock for the development of its lead drug candidate Trappsol Cyclo.